Research in BriefBenefit of Active Treatment in Non–Small-Cell Lung Cancer in Elderly Patients and Patients with Poor Performance Status
References (13)
- et al.
Chemotherapy and radical radiotherapy for patients with inoperable NSCLC aged 70 or over -results of a treatment policy based on performance status and stage at presentation
Lung Cancer
(2003) - et al.
The outcome of combined modality therapy for non-small-cell lung cancer (NSCLC) in the elderly
Lung Cancer
(2003) - et al.
A randomized phase II trial of gemcitabine, vinorelbine or docetaxel in the treatment of elderly and/or poor performance state patients with non-small-cell lung cancer (NSCLC)
Lung Cancer
(2003) - et al.
ECOG 1599: randomized phase II study of paclitaxel/carboplatin vs cisplatin/gemcitabine in performance status (PS) 2 patients with treatment-naive advanced NSCLC
Lung Cancer
(2003) - et al.
Age-specific subanalysis of ECOG 1594: Fit elderly patients (70-80 yrs.) with NSCLC do as well as younger patients (<70)
Lung Cancer
(2003) - et al.
Phase III study (TAX 326) of docetaxelcisplatin (DC) and docetaxel-carboplatin (DCB) versus vinorelbine-cisplatin (VC) for the first-line treatment of advanced/metastatic non-small-cell lung cancer (NSCLC): analyses in elderly patients
Lung Cancer
(2003)
Cited by (4)
Dose intensity correlate with survival in elderly patients treated with chemotherapy for advanced non-small cell lung cancer
2009, Lung CancerCitation Excerpt :As a consequence, frequently in clinical practice an adequate dose intensity (DI) is difficult to be delivered. Since in NSCLC, chemotherapy DI has been related to treatment outcome [6–8], we performed a retrospective analysis on elderly patients treated at our Institution with chemotherapy for advanced NSCLC with the aim of assessing delivered DI and relationship to clinical outcome. This is a retrospective analysis performed on elderly patients with advanced NSCLC treated with chemotherapy at our Institution from January 1998 to June 2007.
Chemotherapy in the Older Patient with Operable Non-Small Cell Lung Cancer: Neoadjuvant and Adjuvant Regimens
2009, Thoracic Surgery ClinicsCitation Excerpt :Additionally, there was no interaction between age and chemotherapy effect, but there was a beneficial interaction between better performance status and treatment effect.5 When considering cisplatin-based adjuvant chemotherapy, poor ECOG performance status (PS 2 or worse) may be a relative contraindication for prescription of adjuvant therapy.78,79 This interaction is particularly pertinent to older patients with an increased frequency and severity of comorbid illnesses and greater vulnerability to physiologic stress.80
Active treatment rates for lung cancer in south manchester: Are we doing enough?
2010, Interactive Cardiovascular and Thoracic Surgery